CANTON – MMS Holdings has restructured its consulting services with the launch of a Project Advisory Services Unit to meet the needs for senior-level guidance for small to mid-sized organizations for specialized consulting, and advisory services.
MMS Project Advisory Services will be led by Jessica Reed, PhD, and includes a growing team of more than 50 expert advisors in regulatory, clinical, nonclinical, compliance and CMC. In this role, Jessica will continue to build on the Company’s strong reputation in helping customers navigate the complexities of the regulatory environment to accelerate their time to market.
“Jessica Reed brings a unique blend of strategic leadership skills, including regulatory and project management expertise that is invaluable to biopharmaceutical companies looking for guidance along the entire continuum of the drug development lifecycle,” said Kelly Hill, Executive Vice President, Business Operations and Strategy, MMS. “Our MMS team of strategic advisors have a long history of helping our Sponsors to develop effective strategies and minimize program and project risks along the way. We look forward to continuing this track record under Jessica’s leadership.”
MMS services portfolio ranges from new chemical entities (NCEs), biologics, biosimilars, well-established substances 505(b)(2) pathway, generic drugs, devices and in-vitro diagnostics. With in-house expertise in drug-device combination products and medical devices, MMS also offers a range of strategic and operational services.
